Survodutide Shows Dual Benefits for Obesity and Liver Disease in Phase 3 Trials

Positive results from two global Phase 3 trials for survodutide demonstrate significant and sustained weight loss, alongside substantial improvements in liver health for patients with MASLD. The drug achieved notable liver fat reductions and normalization in a majority of participants. These findings suggest a promising new treatment option for both obesity and metabolic dysfunction-associated steatotic liver disease.